Patients who are eligible for CXCR4-directed radioligand therapy may be treated with β-emitters such as 177Lu/90Y-PentixaTher, and this approach has been used successfully mainly in the clinical settings of hematological malignancies (50). The gene discussed is CXCR4; the disease is hematologic disorder.